OTCMKTS:RSLSD

ReShape Lifesciences Competitors

Add

Compare

Today's Range N/A

50-Day Range

$5.37

MA: $5.37▼

$5.37

52-Week Range N/A

Volume6,500 shs

Average Volume1,362 shs

Market Capitalization$1.94 million

P/E RatioN/A

Dividend YieldN/A

Beta2.03

ReShape Lifesciences (OTCMKTS:RSLSD) Vs. NIMU, NXNN, ARDMQ, MAGAA, ECTE, and SCIE

Should you be buying RSLSD stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to ReShape Lifesciences, including Non-Invasive Monitoring Systems (NIMU), Nexeon MedSystems (NXNN), Aradigm (ARDMQ), Magna-Lab (MAGAA), Echo Therapeutics (ECTE), and SpectraScience (SCIE).

ReShape Lifesciences vs. Non-Invasive Monitoring Systems Stock

ReShape Lifesciences (OTCMKTS:RSLSD) and Non-Invasive Monitoring Systems (OTCMKTS:NIMU) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and price targets for ReShape Lifesciences and Non-Invasive Monitoring Systems, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	0	0	N/A
Non-Invasive Monitoring Systems	0	0	0	0	N/A

Risk and Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Non-Invasive Monitoring Systems has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.

Profitability

This table compares ReShape Lifesciences and Non-Invasive Monitoring Systems' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-668.58%	-163.22%	-52.10%
Non-Invasive Monitoring Systems	N/A	-2,509.09%	-80.19%

Earnings and Valuation

This table compares ReShape Lifesciences and Non-Invasive Monitoring Systems' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$610,000.00	0.00	$-81,150,000.00	N/A	N/A
Non-Invasive Monitoring Systems	N/A	N/A	$-160,000.00	N/A	N/A

Non-Invasive Monitoring Systems has lower revenue, but higher earnings than ReShape Lifesciences.

Summary

ReShape Lifesciences beats Non-Invasive Monitoring Systems on 4 of the 6 factors compared between the two stocks.

ReShape Lifesciences vs. Nexeon MedSystems Stock

Nexeon MedSystems (OTCMKTS:NXNN) and ReShape Lifesciences (OTCMKTS:RSLSD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Risk and Volatility

Nexeon MedSystems has a beta of 12.71, meaning that its share price is 1,171% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

Profitability

This table compares Nexeon MedSystems and ReShape Lifesciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexeon MedSystems	N/A	N/A	N/A
ReShape Lifesciences	-668.58%	-163.22%	-52.10%

Analyst Recommendations

This is a breakdown of current recommendations for Nexeon MedSystems and ReShape Lifesciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexeon MedSystems	0	0	0	0	N/A
ReShape Lifesciences	0	0	0	0	N/A

Earnings & Valuation

This table compares Nexeon MedSystems and ReShape Lifesciences' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexeon MedSystems	N/A	N/A	N/A	N/A	N/A
ReShape Lifesciences	$610,000.00	0.00	$-81,150,000.00	N/A	N/A

Nexeon MedSystems has higher earnings, but lower revenue than ReShape Lifesciences.

Summary

Nexeon MedSystems beats ReShape Lifesciences on 4 of the 5 factors compared between the two stocks.

ReShape Lifesciences vs. Aradigm Stock

ReShape Lifesciences (OTCMKTS:RSLSD) and Aradigm (OTCMKTS:ARDMQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.

Risk and Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Aradigm has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500.

Profitability

This table compares ReShape Lifesciences and Aradigm's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-668.58%	-163.22%	-52.10%
Aradigm	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for ReShape Lifesciences and Aradigm, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	0	0	N/A
Aradigm	0	0	0	0	N/A

Earnings & Valuation

This table compares ReShape Lifesciences and Aradigm's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$610,000.00	0.00	$-81,150,000.00	N/A	N/A
Aradigm	N/A	N/A	N/A	N/A	N/A

Aradigm has lower revenue, but higher earnings than ReShape Lifesciences.

Summary

Aradigm beats ReShape Lifesciences on 4 of the 5 factors compared between the two stocks.

ReShape Lifesciences vs. Magna-Lab Stock

Magna-Lab (OTCMKTS:MAGAA) and ReShape Lifesciences (OTCMKTS:RSLSD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Magna-Lab and ReShape Lifesciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Magna-Lab	0	0	0	0	N/A
ReShape Lifesciences	0	0	0	0	N/A

Earnings & Valuation

This table compares Magna-Lab and ReShape Lifesciences' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Magna-Lab	N/A	N/A	$-130,000.00	N/A	N/A
ReShape Lifesciences	$610,000.00	0.00	$-81,150,000.00	N/A	N/A

Magna-Lab has higher earnings, but lower revenue than ReShape Lifesciences.

Profitability

This table compares Magna-Lab and ReShape Lifesciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Magna-Lab	N/A	-12.32%	42,399.99%
ReShape Lifesciences	-668.58%	-163.22%	-52.10%

Volatility & Risk

Magna-Lab has a beta of 5.2, indicating that its stock price is 420% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500.

Summary

Magna-Lab beats ReShape Lifesciences on 5 of the 6 factors compared between the two stocks.

ReShape Lifesciences vs. Echo Therapeutics Stock

ReShape Lifesciences (OTCMKTS:RSLSD) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Risk and Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, meaning that its stock price is 609% more volatile than the S&P 500.

Valuation & Earnings

This table compares ReShape Lifesciences and Echo Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$610,000.00	0.00	$-81,150,000.00	N/A	N/A
Echo Therapeutics	N/A	N/A	N/A	N/A	N/A

Echo Therapeutics has lower revenue, but higher earnings than ReShape Lifesciences.

Analyst Ratings

This is a summary of recent ratings and price targets for ReShape Lifesciences and Echo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	0	0	N/A
Echo Therapeutics	0	0	0	0	N/A

Profitability

This table compares ReShape Lifesciences and Echo Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-668.58%	-163.22%	-52.10%
Echo Therapeutics	N/A	N/A	N/A

Summary

Echo Therapeutics beats ReShape Lifesciences on 4 of the 5 factors compared between the two stocks.

ReShape Lifesciences vs. SpectraScience Stock

ReShape Lifesciences (OTCMKTS:RSLSD) and SpectraScience (OTCMKTS:SCIE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Valuation and Earnings

This table compares ReShape Lifesciences and SpectraScience's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$610,000.00	0.00	$-81,150,000.00	N/A	N/A
SpectraScience	N/A	N/A	N/A	N/A	N/A

SpectraScience has lower revenue, but higher earnings than ReShape Lifesciences.

Profitability

This table compares ReShape Lifesciences and SpectraScience's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-668.58%	-163.22%	-52.10%
SpectraScience	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ReShape Lifesciences and SpectraScience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	0	0	N/A
SpectraScience	0	0	0	0	N/A

Risk and Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, SpectraScience has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Summary

SpectraScience beats ReShape Lifesciences on 3 of the 5 factors compared between the two stocks.